Earlier in January 2026, Novavax announced a non-exclusive license and option agreement granting Pfizer worldwide rights to use its Matrix-M adjuvant in vaccine products for up to two infectious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results